PMID- 28322993 OWN - NLM STAT- MEDLINE DCOM- 20170608 LR - 20181113 IS - 1879-0038 (Electronic) IS - 0378-1119 (Print) IS - 0378-1119 (Linking) VI - 618 DP - 2017 Jun 30 TI - Intra-luminal gene therapy in the porcine artery using a recombinant adeno-associated virus 9. PG - 24-27 LID - S0378-1119(17)30177-4 [pii] LID - 10.1016/j.gene.2017.03.019 [doi] AB - The ability to improve or restore blood flow and promote healing in ischemic tissue has many potential clinical applications. Augmentation by direct delivery of growth factors may further enhance results, but requires a method for sustained delivery. In this study, we have tested the ability of adeno-associated virus 9 (AAV9) delivered within the lumen of a porcine artery to transfect the vessel and produce a desired product. The marker chosen was green fluorescent protein (GFP) (Ke et al., 2011). In 4 farm pigs the cranial tibial artery was surgically exposed. The vessel was temporarily clamped proximally, and divided distally. A cannula was placed intraluminally, and the arterial segment was injected with 1x10E13 particles of AAV9.CB7.CI.GFP.WPRE.rBG. At 14days the transfected cranial tibial artery as well as the liver, spleen and kidneys were harvested. ELISA and reverse transcriptase quantitative polymerase chain reaction (RT-qPCR) were used to analyze the artery for GFP production. Significant GFP expression was seen in all transfected cranial tibial vessels, as determined by both GFP protein production (ELISA) and mRNA (RT-qPCR). No GFP was identified in liver, spleen or kidney, nor in the no-GFP control animal artery. Adeno-associated virus 9 is an appropriate vector for gene therapy experiments in the porcine artery model. This vector, and the intraluminal deliver method described result in robust gene expression at 2weeks without evident systemic spill of the virus. The ability to limit delivery of the gene to an isolated segment of vessel is desirable for future research applications. CI - Copyright (c) 2017 Elsevier B.V. All rights reserved. FAU - Rezaie, E S AU - Rezaie ES AD - Mayo Clinic, Department of Orthopedic Surgery, 200 1st St. SW, Rochester, MN 55905, United States. Electronic address: rezaie.elisa@mayo.edu. FAU - Visser, N J AU - Visser NJ AD - Mayo Clinic, Department of Orthopedic Surgery, 200 1st St. SW, Rochester, MN 55905, United States. FAU - Friedrich, P F AU - Friedrich PF AD - Mayo Clinic, Department of Orthopedic Surgery, 200 1st St. SW, Rochester, MN 55905, United States. FAU - Shin, A Y AU - Shin AY AD - Mayo Clinic, Department of Orthopedic Surgery, 200 1st St. SW, Rochester, MN 55905, United States. FAU - Bishop, A T AU - Bishop AT AD - Mayo Clinic, Department of Orthopedic Surgery, 200 1st St. SW, Rochester, MN 55905, United States. LA - eng GR - R01 AR049718/AR/NIAMS NIH HHS/United States PT - Journal Article DEP - 20170318 PL - Netherlands TA - Gene JT - Gene JID - 7706761 RN - 0 (DNA, Recombinant) RN - 147336-22-9 (Green Fluorescent Proteins) SB - IM MH - Animals MH - DNA, Recombinant/administration & dosage/genetics MH - Dependovirus/*genetics MH - Gene Transfer Techniques MH - Genetic Therapy/*methods MH - Genetic Vectors/administration & dosage/genetics MH - Green Fluorescent Proteins/genetics/metabolism MH - Injections, Intra-Arterial MH - Swine MH - *Tibial Arteries PMC - PMC5515074 MID - NIHMS865807 OTO - NOTNLM OT - Adeno associated virus OT - Gene therapy OT - Porcine OT - Vascular disease EDAT- 2017/03/23 06:00 MHDA- 2017/06/09 06:00 PMCR- 2018/06/30 CRDT- 2017/03/22 06:00 PHST- 2017/01/21 00:00 [received] PHST- 2017/02/22 00:00 [revised] PHST- 2017/03/16 00:00 [accepted] PHST- 2017/03/23 06:00 [pubmed] PHST- 2017/06/09 06:00 [medline] PHST- 2017/03/22 06:00 [entrez] PHST- 2018/06/30 00:00 [pmc-release] AID - S0378-1119(17)30177-4 [pii] AID - 10.1016/j.gene.2017.03.019 [doi] PST - ppublish SO - Gene. 2017 Jun 30;618:24-27. doi: 10.1016/j.gene.2017.03.019. Epub 2017 Mar 18.